Supporting the World's Biggest Challenges

Croda International Plc (Croda) today announced that it has signed two new partnership agreements that will help the pharmaceutical industry move towards a more sustainable supply chain for vaccine adjuvants. 

To this day, our focus has been to successfully develop, manufacture and market high-quality adjuvants for our pharmaceutical customers. This heritage makes our vaccine adjuvants unique in the industry. A heritage we are proud of. 

Our industry-leading, Alhydrogel®, Adju-Phos® and Quil-A® are widely recognised in the vaccine industry for their unmatched track record when it comes to a proven history of safe and effective use.

Formulating a drug for parenteral delivery comes with its fair set of challenges. Aside from a high level of sensitivity to external factors like light and heat exposure, these large and complex drugs are prone to degradation when exposed to various chemical species.

For over 40 years Avanti has provided API (Active Pharmaceutical Ingredient) Technology Development for Pharmaceutical and Biotechnology companies. Our unique reputation for quality in the development of pre-clinical and clinical candidates is well established. Our full range of services include process chemistry, scale-up manufacturing, supply chain management with analytical and regulatory requirements. Avanti’s experienced staff of chemists and lipid analysts are ready to meet your development needs with pre-clinical through phase III and commercial launch.

Adjuvants. You’ve seen them on our website. You’ve seen them featured in our blog articles. Now we want to show you how Avanti’ & Croda-Denmark can enhance your vaccine adjuvant research!

Keep reading to learn more!

Croda International Plc, the company that uses smart science to create high performance ingredients and technologies that improve lives, is excited to announce the expansion of its Mill Hall high purity excipients facility. This investment confirms Croda’s commitment to building its Life Sciences business and developing innovative pharmaceutical excipients, reinforcing Croda’s Purpose to use Smart science to improve lives™. With this latest Mill Hall expansion, Croda continues their ambitious target to become People Positive by 2030 by contributing to the successful development of 25% of WHO-listed pipeline vaccines.

To find out more, please visit: https://www.croda.com/en-gb/news/2021/08/croda-expands-its-high-purity-pharmaceutical-excipients-manufacturing-capability

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

The transaction will more than double Croda’s R&D capability in drug delivery.

We are pleased to provide the following overview of Croda’s current status regarding the relevant supplier targets announced.

Produced using cutting-edge technology that centres on synthetic biology, our pharmaceutical-grade squalene has superior purity, naturally setting it apart.

Find out what steps you can take to help ensure that everyone gets the vaccines they need.

REACH-compliant, compendial, sustainable, optimised for use in biomanufacturing of recombinant proteins, blood fractionation products, viral vectors and more!

We are specialised in the extraction and purification of phospholipids for pharmaceutical and nutraceutical applications.

The use of cannabinoids (CBD) is a growing marketplace dominated by oral and topical formulations. Croda offers Super Refined™ formulation solutions providing benefits such as; improving stability and reducing taste impact. Find out more here:

Super Refined™ Polysorbates for Biopharma applications.

This document is relevant to the following market areas

Health Care - DermaHealth Care - Pharma
Health Care - Nutra
Health Care - Animal Health

This document is attached to the following products

Super Refined™ Polysorbate 80

Pharmaceutical excipients for ophthalmic formulations.

This document is relevant to the following market areas

Health Care - Derma
Health Care - Pharma
Health Care - Nutra
Health Care - Animal Health

Super Refined™ pharmaceutical excipients.